Suppression of Urokinase Receptor Expression by Thalidomide Is Associated with Inhibition of Nuclear Factor κB Activation and Subsequently Suppressed Ovarian Cancer Dissemination
Open Access
- 15 November 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (22) , 10464-10471
Abstract
Thalidomide has been used to treat a variety of diseases ranging from alleviation of autoimmune disorders to prevention of metastasis of cancers. It has been shown previously that increased levels of urokinase-type plasminogen activator receptor (uPAR) correlate well with higher invasive phenotype. We examined whether thalidomide is able to suppress the expression of uPAR mRNA and protein in human ovarian cancer cell line HRA and human chondrosarcoma cell line HCS-2/8. Here, we show that: (a) thalidomide suppresses the expression of constitutive and transforming growth factor-β1 (TGF-β1)–induced uPAR mRNA and protein; (b) a nuclear factor κB (NF-κB) activation system (phosphorylation of IκB-α and degradation of IκB-α) is necessary for the TGF-β1-induced increase in uPAR expression, because l-1-tosylamido-2-phenylethyl chloromethyl ketone, a NF-κB inhibitor, reduced the uPAR production as well as mRNA expression; (c) thalidomide failed to further strengthen l-1-tosylamido-2-phenylethyl chloromethyl ketone's action; (d) the once-daily i.p. administration of thalidomide (400 μg/g body weight/d) decreased progressive growth of HRA tumors and ascites formation in an in vivo animal model; and (e) the once-daily i.p. administration of thalidomide in combination with paclitaxel (i.p., 100 μg/20 g at days 2 and 5) significantly decreased progressive growth of HRA cells in a synergistic fashion. We conclude that thalidomide down-regulates constitutive and TGF-β1-stimulated uPAR mRNA and protein expression possibly through suppression of NF-κB activation. Furthermore, combination therapy with thalidomide plus paclitaxel may be an effective way to markedly reduce i.p. tumor growth and ascites in ovarian cancer dissemination.Keywords
This publication has 37 references indexed in Scilit:
- ThalidomideThe Lancet, 2004
- Suppression of Urokinase Expression and Invasiveness by Urinary Trypsin Inhibitor Is Mediated through Inhibition of Protein Kinase C- and MEK/ERK/c-Jun-dependent Signaling PathwaysJournal of Biological Chemistry, 2001
- Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87)Cancer Gene Therapy, 2000
- Deregulation of the signaling pathways controlling urokinase productionEuropean Journal of Biochemistry, 1999
- Myosin Light Chain Kinase Functions Downstream of Ras/ERK to Promote Migration of Urokinase-type Plasminogen Activator-stimulated Cells in an Integrin-selective MannerJournal of Cell Biology, 1999
- Binding of Urokinase-type Plasminogen Activator to Its Receptor in MCF-7 Cells Activates Extracellular Signal-regulated Kinase 1 and 2 Which Is Required for Increased Cellular MotilityJournal of Biological Chemistry, 1998
- Transcriptional activation of the urokinase receptor gene in invasive colon cancerInternational Journal of Cancer, 1994
- Urokinase receptor and colorectal cancer survivalThe Lancet, 1994
- Recombinant soluble urokinase receptor as a scavenger for urokinase‐type plasminogen activator (uPA)FEBS Letters, 1994
- The Urokinase Receptor: Involvement in Cell Surface Proteolysis and Cancer InvasionAnnals of the New York Academy of Sciences, 1992